DSIP for Sleep: What the Research Actually Shows
DSIP, short for delta sleep-inducing peptide and also referred to by the name emideltide, is a nonapeptide first isolated from the blood of sleeping rabbits in the 1970s. The "delta sleep" in its name refers to slow-wave sleep, the deep stage marked by delta-frequency EEG activity, which is what researchers were looking for when they named it. A name assigned at discovery is a hypothesis, not a result. The question this page answers is narrow: what does the actual human sleep-trial evidence say, separate from the peptide's branding.
Is there a real human trial, and what did it find?
Yes, one that we can point to. A double-blind study examined the effects of delta sleep-inducing peptide on sleep in chronic insomniac patients (Neuropsychobiology, 1992). This is the closest thing to direct clinical evidence for DSIP as a sleep intervention, and it deserves scrutiny rather than a headline.
What we can say from a study of this era and design, published as a brief double-blind trial in chronic insomniacs: it reports mixed results rather than a uniform improvement across the group. What we cannot say, because the abstract-level record does not support it, is the specific sample size, the dosing regimen, the exact sleep-architecture endpoints measured, or whether findings replicated in any later trial. No such replication appears in the sources available here. A single small trial from 1992, in a pre-modern polysomnography era, with mixed outcomes, is a starting hypothesis, not a validated treatment effect. Anyone citing this study as proof DSIP "works for sleep" is overstating what one 30-plus-year-old paper with mixed results can carry.
Why does most of the other DSIP literature not answer the sleep question?
Because it was not designed to. The bulk of the DSIP research base sourced here is animal, in vitro, or mechanistic work on entirely different endpoints:
- Antioxidant enzyme expression and lysosomal/mitochondrial function in aging rat tissue (gene expression, lysosomal membranes, mitochondrial electron transport, tissue antioxidant status)
- Metabolic effects during physiological aging in rats (metabolic study)
- Hepatocyte function under foot-shock stress in rats (stress model)
- Effects on plasma ACTH after intravenous DSIP in humans, a stress-axis endpoint, not a sleep endpoint (ACTH reduction study)
- EEG and heart rate variability changes when DSIP was used as an anesthesia adjunct under isoflurane, a surgical context unrelated to insomnia treatment (anaesthesia adjunct study)
- Neuronal activity changes in rat hippocampus after emotional-structure stimulation (hippocampal study)
- Hydrogel and polymer matrix entrapment and release characteristics, formulation chemistry, not efficacy (hydrogel entrapment, macroporous matrices)
- Comparative biological properties of a related oligopeptide proposed as an endogenous DSIP prototype (KND oligopeptide study)
None of this is irrelevant to understanding DSIP as a molecule. It is relevant to the wrong question if a reader wants to know whether it improves sleep in people. Citing an aging-rat mitochondrial paper as support for a human sleep claim is a category error, and it is a common one in peptide marketing copy.
Does the "delta sleep" name mean it increases slow-wave sleep?
Not established, based on what is available here. The name reflects the discovery context, isolation from blood during deep sleep phases in animal models, not a confirmed mechanism of inducing delta-wave activity in human sleep studies. The anesthesia-adjunct study does report DSIP altering bispectral index and EEG measures, but bispectral index during isoflurane anesthesia is a different physiological state than natural sleep onset or maintenance in an insomnia patient, and the finding does not transfer directly. If a reader wants to understand the proposed biological mechanism in more depth, that discussion belongs on a dedicated mechanism page rather than folded into the sleep-evidence question, because mechanism plausibility and clinical outcome are separate claims that get conflated constantly in DSIP marketing.
How does this compare to melatonin or prescription sleep aids, evidence-wise?
It does not compare favorably on trial volume or regulatory standing. Melatonin and prescription hypnotics such as zolpidem have substantially larger human trial bases and, in the case of prescription drugs, FDA-approved indications with labeled dosing. DSIP has no FDA-approved indication for any use. A side-by-side look at the evidence bases lives on the DSIP versus melatonin comparison and DSIP versus prescription sleep aids pages. Readers currently on a prescription hypnotic who are considering a change should not use this page as guidance for tapering; that is a separate clinical decision covered in the zolpidem discontinuation protocol and trazodone discontinuation protocol pages.
What is the current regulatory status, and does it affect the evidence question?
It affects sourcing, not the trial data itself, but readers should know it. DSIP has no FDA-approved application. Its nomination for the FDA's Category 2 bulk drug substance list was withdrawn by the nominators themselves, per the FDA's Category 2 bulk substances page (content current as of 04/22/2026). Withdrawal is not the same as approval or a safety clearance, and DSIP does not appear on the 503A bulk drug substances list, meaning no enforcement discretion currently covers compounding it. In a July 23-24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted against recommending emideltide (DSIP) for that 503A list, a decision documented on the committee's meeting page. This is a rejection, not a pending or favorable regulatory signal, and it should not be read as momentum toward future approval. For the fuller regulatory picture, see DSIP's FDA status in 2026 and the FDA Peptide Status Tracker.
Reading a peptide sleep trial: a quick evidence-boundary checklist
Before treating any single study as proof of a sleep benefit, a reader can walk through these questions, which apply to DSIP and to most peptide sleep claims circulating online.
| Question | Why it matters | DSIP's 1992 trial |
|---|---|---|
| Was it conducted in the population you care about (chronic insomniacs, not surgical patients or lab animals)? | Findings in rats or anesthesia patients do not transfer to insomnia treatment claims | Yes, chronic insomniac patients |
| Was the result a clean positive, or mixed/partial? | Mixed results should not be marketed as a clear win | Reported as mixed |
| Has it been replicated in a later, larger, or better-designed trial? | A single small trial is a hypothesis generator, not confirmation | No replication identified in available sources |
| Does the study measure the endpoint you actually care about (sleep onset, maintenance, architecture) rather than a downstream biomarker? | Cortisol, ACTH, or enzyme changes are not the same as "you sleep better" | Endpoint detail not available at abstract level here |
| Is the era of the study consistent with modern measurement standards (validated polysomnography, standardized scales)? | Pre-1990s sleep trials often lack methods rigor by current standards | 1992, dated methodology likely |
| Does the source carry regulatory or guideline weight, or is it observational/mechanistic only? | Determines how much clinical weight the finding should carry | Small clinical trial, no regulatory backing, no guideline mention |
Run any DSIP sleep claim through this table before accepting it. Most marketing claims for DSIP as a sleep aid fail on the replication and endpoint-specificity rows.
What is established, what is plausible, and what is not established
Established: DSIP is a peptide studied since the 1970s with a documented, though small and dated, body of research including one identified double-blind human trial in insomnia patients showing mixed results. It has no FDA-approved indication, and its bulk-substance nomination was withdrawn and separately rejected by an FDA advisory committee for 503A compounding purposes.
Plausible but unproven: that DSIP has some effect on sleep-related physiology in humans, given the one trial and various stress-hormone findings such as the ACTH study. Plausibility is not the same as a demonstrated clinical benefit for insomnia.
Not established: that DSIP reliably improves sleep onset, maintenance, or quality in humans at any specific dose; that it increases delta-wave slow-wave sleep in a way consistent with its name; that animal aging, metabolic, or antioxidant findings translate into a human sleep benefit; or that any current sourcing or compounding pathway is FDA-sanctioned. Readers considering DSIP for sleep should treat the evidence as preliminary and should discuss any peptide use with a prescriber, particularly if they have an existing sleep disorder diagnosis or are on other sedative-hypnotic medications, since interaction data is not available in current sourcing. For background on general practice standards and side effect reporting, see DSIP side effects and safety and what DSIP is.